Glimipine-MV2 is a triple-action therapy for type 2 diabetes, combining key ingredients to regulate blood sugar levels effectively. It improves insulin sensitivity, reduces glucose production, and slows carbohydrate absorption, ensuring consistent glycemic control for better diabetes management.
₹ 130
Test | Specifications | Results |
---|---|---|
Description | White & orange colour elongated shape bilayered one side scored uncoated bilayered tablet. | White & orange colour elongated shape bilayered one side scored uncoated bilayered tablet. |
Identification By UV | A 0.001 per cent w/v solution of metformin hydrochloride WS and test solution, as obtained in the assay, shows absorption maxima at 232 nm. | Complies |
Identification By HPLC | In the assay of glimepiride the principal peak in the chromatogram obtained with the test solution correspondsto the principal peak in the chromatogram obtained with the reference solution. | Complies |
Average wt. of tablet | 880 mg ± 5% (836.0 mg to 924.0 mg) | 884.5 mg |
Uniformity of wt. | Average weight. ± 5% | Max +2.88% Min -1.41% |
Dissolution of Glimepiride | NLT 75% of the stated amount | Min - 95.86% to Max - 105.42% |
Dissolution of Metformin HCL:(Sustained Release) I- For 1st hour 2- For 3rd hour 3- For 10th hour |
1- Between (25% to 50%) 2- Between (45% to 75%) 3- (NLT 80% of the stated amount) |
Min - 34.7% to Max - 36.0% Min - 67.0% to Max - 70.0% Min - 89.1% to Max - 91.4% |
Friability | NMT 1.0% | 0.15% |
Uniformity of Content (Glimepiride) | Between 85.0% 115.0% | Complies |
ASSAY:- (Each uncoated bilayered tablet
contains) Glimepiride IP 2mg |
1.8 mg to 2.2 mg & 90% to 110% | 2.0259 mg & 101.30% |
ASSAY:- (Each uncoated bilayered tablet
contains) Metformin Hydrochloride(As Sustained Release) IP 500mg |
450 0 mg to 550.0 mg & 90% to 110% | 490.54 mg & 98.11% |
ASSAY:- (Each uncoated bilayered tablet
contains) Voglibose IP 0.2mg |
0.18 mg to 0.22 mg & 90% to 110% | 0.1982 mg & 99.10% |